NCT06904807 - A Phase I Study to Evaluate LIFE-001 | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Healthy Volunteers

Interventions

DRUG

LIFE-001

Single dose of LIFE-001 between 10mg and 300mg administered subcutaneously

DRUG

Placebo

Single dose of placebo comparator administered subcutaneously

DRUG

LIFE-001

Four doses of LIFE-001 between 50mg and 300mg administered subcutaneously seven days apart

DRUG

Placebo

Four doses of placebo comparator administered subcutaneously seven days apart

Trial Locations (1)

RECRUITING

Veritus Research Pty Ltd, Bayswater